GlassScriptPhysician profile
Hanan Malik
NPI 1447443288
$1,205.47
in general payments reported to CMS, 2019-2025
13 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $81.51 · 2021: $90.72 · 2022: $159 · 2023: $91.12 · 2024: $116 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.75 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $417.44 | 2019-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $157.02 | 2023-2025 | Fasenra, Symbicort |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.73 | 2019-2025 | Ofev |
| Merck Sharp & Dohme LLC | $100.00 | 2019 | |
| Grifols USA, LLC | $74.76 | 2022-2025 | Prolastin-C Liquid |
| Astellas Pharma US INC | $68.99 | 2024 | |
| Mylan Specialty L.P. | $52.72 | 2019-2022 | |
| Electromed, INC. | $51.85 | 2025 | Smartvest |
| Amgen INC. | $39.94 | 2025 | Tezspire, Tavneos |
| Baxter Healthcare | $33.95 | 2022 | |
| Genzyme Corporation | $32.64 | 2025 | |
| Olympus America INC. | $27.78 | 2024 | Spin Vision Video Processor |
| Bayer Healthcare Pharmaceuticals INC. | $17.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanan Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.